SequelSEC

ProMIS Neurosciences Inc. PMN

Pharmaceutical Preparations · CIK 0001374339 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$40.17M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

ProMIS Neurosciences Inc. (PMN) reported net income of -$39.72M for the fiscal year ended 2025-12-31. This page shows 5 annual periods of income statement, balance sheet and cash flow figures normalized from ProMIS Neurosciences Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ProMIS Neurosciences Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$40.17M-$16.83M-$14.26M-$23.38M-$8.29M
Net income-$39.72M$2.78M-$13.21M-$18.06M-$9.79M
Research & development$33.38M$10.64M$7.88M$16.09M$4.63M
Weighted-average diluted sharesshares 1.76Mshares 1.06Mshares 12.29Mshares 7.50Mshares 5.79M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailable$0$0$0Unavailable
Diluted EPS$-22.61$2.63$-1.07$-2.41$-1.69
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$6.79M$6.19M$6.38M$7.29M$3.66M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

ProMIS Neurosciences Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-31
Cash & equivalents$6.12M$13.29M$12.60M$5.88M$16.94M
Total assets$9.18M$18.91M$13.62M$6.92M$17.75M
Current assets$9.18M$18.91M$13.62M$6.90M$17.71M
Total liabilities$10.44M$2.42M$9.87M$8.27M$12.09M
Current liabilities$10.41M$2.22M$9.35M$6.41M$929.07K
Total equity incl. NCI-$1.26M$16.49M$3.75M-$1.35M$5.66M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailable$0Unavailable$3.91M
Accounts payable$2.54M$1.74M$7.84M$2.98M$408.98K

Cash flow

ProMIS Neurosciences Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-31
Operating cash flow-$28.12M-$27.18M-$10.84M-$17.03M-$9.31M
Capital expendituresUnavailableUnavailableUnavailable$1.98K$6.04K
Investing cash flow-$702-$693-$1.35K-$1.98K$94.62K
Financing cash flow$20.94M$27.88M$17.75M$6.49M$25.52M
Net change in cash-$7.17M$693.02K$6.72M-$11.07M$16.14M
Stock-based compensation$857.63K$825.81K$271.54K$487.63K$515.63K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

ProMIS Neurosciences Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-31
Free cash flowUnavailableUnavailableUnavailable-$17.04M-$9.31M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.88x8.52x1.46x1.08x19.07x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PMN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-25View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.